Back to News
Market Impact: 0.2
Zentalis Highlights Interim Survival Data From DENALI Part 1b Study Of Azenosertib In PROC
Source: Nasdaq
Healthcare & Biotech
Zentalis Pharmaceuticals said interim overall-survival data from Part 1b of its Phase 2 DENALI (GOG-3066) trial of azenosertib in platinum-resistant ovarian cancer were published in an abstract ahead of a rapid oral presentation. The provided article text contains no survival figures or trial outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ZNTL0.30
More News
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper